Back to News
Market Impact: 0.35
U.S. FDA extends review of Exelixis' cancer drug
Source: reuters.com
Healthcare & BiotechRegulation & Legislation
The FDA extended its review of Exelixis' experimental colorectal-cancer drug combination by three months. The delay postpones a potential regulatory decision and could defer commercialization timelines, creating a near-term overhang for Exelixis shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
EXEL-0.55
More News
- Exelixis stock falls as FDA extends zanzalintinib review
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- US legislators push AI safety laws amid human extinction warnings
- Flavio Bolsonaro faces corruption probe weeks before Brazil election
- Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)